Fresenius Invests to Help Humacyte Develop Implantable Blood Vessels
Fresenius has invested an additional $25 million in Humacyte Inc, to help the implantable vessel company get market approval. The new vessels, which can be used to create and repair vascular accesses, are now being tested in a clinical trial for use in dialysis.
Read the full article » | Posted 09-14-2021
Related Articles
- Death of Cannulation Expert, Educator and Home Dialysis Champion, Stuart Mott Posted 07-12-2024
- PD and Home HD Sessions and Posters from the 2024 NKF Spring Clinicals Posted 06-14-2024
- New, Validated Survey of Home Dialysis Patients’ Experience of Care Posted 06-14-2024
- Baxter Launches MyPD Digital Management App in Korea Posted 06-14-2024